Enterprise Value

14.18B

Cash

12.5B

Avg Qtr Burn

N/A

Short % of Float

0.00%

Insider Ownership

65.11%

Institutional Own.

18.18%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
COMIRNATY (BNT162b2) Details
COVID-19, Infectious disease

Approved

Quarterly sales

BNT316 (ONC-392) Details
Non-small cell lung carcinoma, Cancer, Lung cancer

Phase 3

Initiation

BNT113 Details
Head and neck cancer, Human papillomavirus

Phase 2

Data readout

Phase 2

Data readout

Autogene cevumeran (BNT122) (RO7198457) Details
Solid tumor/s, Colorectal cancer

Phase 2

Data readout

Phase 2

Interim update

Phase 2

Initiation

BNT-211 Details
Solid tumor/s, Cancer

Phase 1/2

Data readout

BNT323 (DB-1303) Details
Cancer, Solid tumor/s

Phase 1/2

Data readout

BNT-167 Details
Vaccine, Shingles

Phase 1/2

Update

Autogene Cevumeran (BNT122) (w/ atezolizumab) Details
Solid tumor/s, Non-small cell lung carcinoma, Bladder cancer, Melanoma

Phase 1/2

Update

BNT-164 Details
Vaccine, Tuberculosis

Phase 1

Update